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Available online 27 September 2014AbstractPurpose: Menopause may be associated with some adverse changes, such as oral dryness (OD) feeling. The exact mechanisms that
mediate sensation of OD in menopausal women have not been firmly established. The purpose of the present study was to assess the
relationship of un-stimulated whole saliva cortisol and chromogranin A (CgA) levels with OD feeling in post-menopausal women.
Materials & methods: : The present study was conducted on eighty selected post-menopausal women with/without xerostomia.
Subjects were equally divided into two groups, forty patients each. Group I: (study group) constituted by 40 female subjects
meeting the selection criteria and having xerostomia. Group II: (control group) constituted by 40 female subjects meeting the same
criteria with the exception of the presence of xerostomia. Un-stimulated whole saliva cortisol and chromogranin A concentrations
were measured by ELISA (enzyme-linked immunosorbent assay). Collected data of the present study was tabulated and statistically
analyzed using the statistical software package.
Results: The means of salivary cortisol and chromogranin A concentrations were significantly higher with significantly decrease in
the mean un-stimulated salivary flow rate (UWSFR) in group I (xerostomia group) compared to group II (control group)
(P  0.001).
Conclusion: Significant associations between salivary cortisol and CgA levels and symptoms of oral dryness and reduced salivary
flow rates were detected.
© 2014, Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
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Menopause is defined as the permanent (after 12
months) cessation of menstruation resulting from the
loss of ovarian function. The age at which physiolog-
ical menopause appears is between 45 and 55 years,
with an average of 52.5 years [1]. Utian, (1999) [2]
classified menopause stages to: 1- Pre-menopause:entistry, Tanta University.
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period, 2- Peri-menopause: the time immediately
around the menopause, often accompanied by longer
cycles and heavier and prolonged bleeding. These
menstrual irregularities are due to decline in ovarian
follicular function, but no 12 consecutive months of
amenorrhea (lack of menstruation) have yet occurred.
This stage is often accompanied by hot flushes. The
average age of peri-menopause is 45.1 years but it can
start any time between ages 39 and 51, and can last
between two and eight years (the average being five),
3- Post-menopause: a period of time where no
menstruation has occurred in 12 consecutive months.
The median age for this to happen is 51 years.
When a woman is post-menopausal, she has some
additional long-term age-related health considerations
such as the development of osteoporosis and cardio-
vascular disease. As a woman reaches the menopause
stages of life, it is a good opportunity to assess overall
health and lifestyle choices to address potential long-
term health issues. The issue of menopause and post-
menopausal health in women is of significance to so-
ciety in general because of the universality of meno-
pause, it affects all women and because of the
unprecedented increase in the number of post-
menopausal women [3].
Premature menopause is defined as occurring when a
woman is less than two standard deviations below the
median age for menopause in the referred population.
Age of 40 yrs is often used as an arbitrary age below
which the menopause is viewed as premature. There are
primary and secondary premature ovarian failure [4].
The fall in hormones (estrogen and progesterone)
levels at the post-menopause can cause a variety of
symptoms such as hot flushes, night sweating, palpi-
tation, headache, changes in the skin, brittle nails, hair
loss, muscular aches, osteoporosis, Irregular menstrual
periods, diminished sexual function, variable signs or
symptoms which reflecting a depressed mood and oral
discomfort [5e9]).
Oral discomfort is characterized by a burning
sensation, sensation of oral dryness (xerostomia or dry
mouth) and decreased saliva secretion (hypo-salivation
or hypo-function) [10].
Xerostomia is a common oral concern for many
patients. It is estimated that up to 10 percent of the
general population experiences persistent oral dryness
[11,12]. Xerostomia is more frequent with increasing
age because the number of acini reduces and the
amount of fatty and fibrous tissue increases, and over
25 percent of elders complain of daily dryness espe-
cially in post-menopausal women [13].However, it does not necessarily relate to decreased
salivary flow rate (hypo-function) in up to one third of
cases. Although salivary gland failure may lead to OD,
the subjective experience of xerostomia is not a reli-
able indicator of salivary gland hypo-function. it may
also occur with the changes in the quality of saliva,
while the amounts of saliva stay unchanged [14,15].
OD can lead to considerable difficulty in speaking,
eating and tasting, and predispose mucosa to wounds,
abrasion and infection [16e18].
Saliva can be considered a filtrate of the serum in as
much as it is derived from the blood. It follows that the
process of saliva production is linked to overall body
fluid balance and that blood flow through salivary
gland tissues (from branches of the maxillary and other
arteries) has a major effect on the production of saliva.
So, saliva is a good indicator of the plasma levels of
various substances such as hormones and drugs and
can therefore be used as a non-invasive method for
monitoring plasma concentrations of medicines or
other substances [19,20].
Total or whole saliva refers to the complex mixture
of fluids from the salivary glands, the gingival fold
(crevicular space), oral mucosa transudate, in addition
to mucous of the nasal cavity and pharynx, non-
adherent oral bacterial, food remainders, desqua-
mated epithelial and blood cells, as well as traces of
medications or chemical products [21].
So, the knowledge of normal salivary flow rate
(SFR) is extremely important when treating dental
patients. Early diagnosis and treatment of xerostomia
and hypo-salivation will preserve the health of oral
structures or tissues and lower the incidence of dental
caries, fungal infections, and other oral diseases that
could result from insufficient SFR. However, it re-
ceives little attention until its quantity diminishes or its
quality becomes altered [22].
For 40 years, endocrinologists have used saliva as a
supplementary sample matrix. Prior reviews, from Riad
et al., (1982) [23] to lewis, (2006) [24], have focused on
salivary analysis of many steroids, although numerous
reported studies have demonstrated that saliva moni-
toring is a useful alternative method for analyzing
hormones of other biochemical origins.
In addition, numerous publications have described
the use of salivary hormone analysis in many fields of
clinical and basic research to diagnose systemic ill-
nesses, monitoring general health, and as an indicator
of risk for diseases creating a close relation between
oral and systemic health [25,26].
Salivary biomarkers such as salivary chromogranin
A (CgA) and salivary cortisol are being explored as a
Table 1
Questionnaire used for selection of subjects with xerostomia.
1 Does your mouth feel dry when eating a meal?
2 Do you have difficulties swallowing any foods?
3 Do you need to sip liquids to aid in swallowing dry foods?
4 Does the amount of saliva in your mouth seem to be reduced
most of the time?
5 Does your mouth feel dry at night or on awakening?
6 Does your mouth feel dry during the daytime?
7 Do you chew gum or use candy to relieve oral dryness?
8 Do you usually wake up thirsty at night?
9 Do you have problems in tasting food?
10 Does your tongue burn?
Response options
Yes/no
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diagnosis of disease. Disorders and diseases in which
saliva may aid in diagnosis include but are by no
means limited to human immune deficiency virus
(HIV) and cancer [27,28].
Cortisol, released by adrenal glands, is the main
glucocorticoid in the human hormonal system and is
responsible for some critical homeostatic tasks, such as
vascular reactivity. Cortisol follows a circadian rhythm
with peak level at about 8.00 a.m. and its nadir in the
late evening [29e31].
Chromogranin A (CgA) is an acidic protein that
consists of 439 amino acids encoded on chromosome
14. CgA is the main member/element of the chro-
mogranins family consisting of water soluble acidic
glycoproteins which is a prohormone discovered for
the first time in the secretory granules from adrenal
medullary chromaffin cells and released into the cir-
culation after splanchnic nerve stimulation together
with catecholamine. The secretion granules from the
chromaffin like cells of the medullo-infrarenal system
store a complex mixture of the molecules which are
today known as catecholamine, and additionally a large
number of precursor proteins of the antimicrobial
peptides like chromogranins, secretogranins and pro-
encephalin A [32,33].
CgA was also recovered in biological fluids impli-
cated in defense mechanisms like abscess fluids or
saliva as CgA be released into saliva from salivary
glands including submandibular gland [34].
Based on the above, the purpose of the present study
was to investigate the salivary levels of cortisol and
CgA in post-menopausal women with xerostomia and
compared to those without xerostomia.
2. Materials & methods
The present study was conducted on 80 female
subjects in the post-menopausal period selected from
the outpatient Clinic of Oral Medicine, Periodontology,
Oral diagnosis and Radiology Department, Faculty of
Dentistry, Tanta University.
The present study was approved by the Research
Ethical Committee of Tanta University. Written
informed consent from patients was obtained. The
subjects used for this study were females in the post-
menopause period, age of 45e55 years, cessation of
menstruation for at least 12 continuous months and
with or without a complain of xerostomia. Patient
having any of the following are not involved in the
current study:1 patients suffering xerostomia produced by specific
causes such as:
a) Local inflammation, focal infection and fibrosis
of the major salivary glands.
b) Autoimmune diseases e.g. Sj€ogrens syndrome
(primary and secondary) and Mikulicz's disease.
c) Malnutrition e.g. anorexia, dehydration.
d) Alcoholism or smoking.
e) Systemic diseases as diabetes or hypertension
or thyroid disease (hypo- and hyper-thyroidism)
and late stage liver disease.
2 The use of hormonal replacement therapy (HRT)
e.g. Estrogen or Estrogen/Progestin products.
3 The use of medications known to affect salivary
gland flow rate such as diuretics, anti-spasmodic,
expectorants, econgestants, systemic bronchodi-
lator … ..etc.
4 Patients under treatment for xerostomia.
5 Past history of radiotherapy or chemotherapy as in
cancer treatments.
To diagnose xerostomia, a questionnaire was
applied to the patients to be answered by yes or no
illustrating presence of xerostomia [35,36] (Table 1).
Response options yes/no. Subjects who had at least
one positive response entered the study group, and
those without any positive responses, formed the con-
trol group. Once xerostomia were reported, patients
were questioned about duration (onset) of xerostomia
and menopause [37].
The selected patients divided into two equal groups
according to their complain of xerostomia
Group I (study group) 40 female subjects having
xerostomia.
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having xerostomia.
2.1. Clinical work
2.1.1. Materials
The salivary flow measurements for all patients
were done according to Walsh, 2010 [38] (Fig. 1).
Determining un-stimulated whole salivary flow
rates (UWSFRs) was done by the spitting or expec-
torating technique. The subjects were told to refrain
from eating and drinking at least one hour prior to the
examination time (between 9:00 a.m. and noon) for all
patients to minimize any circadian rhythm effects and
so to avoid variation in salivary flow rates. Before
taking a sample of saliva, subjects were allowed to
rest for 30e60 min the subjects were asked to sit in a
quiet position with the head tilted forward, they were
asked to rinse their mouth with water in order to
eliminate any possible detritus and to obtain a clean
sample [39].
Each sample was obtained by having the patient
expectorate or spit all saliva into a graduated test tube
through a glass funnel every 1 min, for 10 min. Once
the sample had been obtained it was allowed to settle,
placing the tube in a test tube rack, in order to achieve
a better reading of the saliva volume. Then, volume of
saliva was measured with milliliters (mL) and USFR
was calculated by division volume on minutes (mL/Fig. 1. Tubes graduated in milliliters, a glass funnel and a plastic
container used for saliva collection.min). USFR <0.1 mL/min are considered abnormally
low and indicative of marked salivary hypo function,
however, USFR 0.1 mL/min to 0.3 mL/min are
considered xerostomia. Then the sample was sent to
the laboratory and was centrifuged at 3000 rpm at least
once in order to separate the mucin and frozen at
20 C to 30 C until further analysis to find salivary
cortisol & CgA concentrations (mg/dl) [40,41].
2.2. Laboratory work
2.2.1. Analysis of saliva
From each of the collected saliva sample, an equal
volume (100 mL) was taken for measurement of sali-
vary chromogranin A (CgA) level and salivary cortisol
level using commercial kits [42] (Fig. 2).
2.2.1.1. DRG salivary cortisol ELISA1
2.2.1.1.1. Assay principle. The DRG Salivary
cortisol ELISA kit was based on the competition prin-
ciple and the micro plate separation. An unknown
amount of cortisol presented in the sample and a fixed
amount of cortisol conjugated with horse-radish
peroxidase competed for the binding sites of mouse
monoclonal cortisol-antiserum coated onto the wells.
After one hour incubation, the micro plate was washed
to stop the competition reaction. After addition of the
substrate solution the concentration of cortisol was
inversely proportional to the optical density measured.
2.2.1.2. DRG salivary chromogranin A (CgA) ELISA2
2.2.1.2.1. Assay principle. This ELISA was
designed, developed and produced for the quantitative
measurement of human CgA in saliva sample. The
assay utilized the two-site “sandwich” technique with
two selected antibodies that bonded to different epi-
topes of human CgA.
Assay standards, controls and patient samples were
added directly to wells of micro plate that was coated
with a polyclonal CgA antibody. After the first incu-
bation period, the antibody on the wall of micro titer
well captures human CgA in the sample and unbound
proteins in each micro titer well were washed away.
Then a horseradish peroxidase (HRP) labeled
monoclonal anti-human CgA antibody was added to
each micro titer well and a “sandwich” of “monoclonal1 (DRG International, Inc., USA. Cat. NO. SLV-2930) for salivary
Cortisol.
2 (DRG International, Inc., USA. Cat. NO. SLV-4521) for salivary
Chromogranin A (CgA).
Fig. 2. ELISA commercial kits of salivary cortisol and salivary
chromogranin A.
Table 2
Comparison of the mean score and standard deviation (SD) of the
clinical and laboratory results between the two groups.
Group I
Mean ± SD
Group II
Mean SD
P value
Volume (ml) 2.1 ± 0.978 6.5 ± 1.16 0.001*
Duration (min) 10 0 10 0 0.996
UWSFR (ml/min) 0.21 ± 0.097 0.65 ± 0.116 0.001*
Cortisol. Conc (mg/dl) 18.5 ± 4.32 0.855 ± 0.308 0.001*
CgA. Conc (mg/dl) 5.02 ± 1.06 0.459 ± 0.181 0.001*
Statistically significant at 5% level.
Fig. 3. Comparison of the mean value of the salivary volume in
group I versus group II.
Fig. 4. Comparison of the mean value of USFR in group I versus
group II.
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formed. The unbound monoclonal antibody was
removed in the subsequent washing step.
For the detection of this immune complex, the well
was incubated with a substrate solution in a timed re-
action and then measured in a spectrophotometric
micro plate reader. The enzymatic activity of the im-
mune complex bound to the CgA on the wall of the
micro titer well was directly proportional to the
amount of CgA in the sample.
2.3. Statistical analysis
The data of the present study was collected, tabu-
lated and statistically analyzed using the statistical
software package SPSS version 11.0 statistical pack-
age. For comparison of both mean variables for each
group the student, s t test was used.
3. Results
Regarding the mean value of the salivary volume
taken during ten minutes in group I (study) compared
to group II (control), there was a statistically significant
decrease in the salivary volume in group I as the P
value was 0.001 (Table 2 & Fig. 3).
Comparing the mean value of the un-stimulated
salivary flow rate taken during ten minutes in group I
compared to group II, there was a statistically signifi-
cant decrease in the un-stimulated salivary flow rate in
group I compared to group II subjects
(P  0.001)(Table 2 & Fig. 4).
Concerning the mean value of the salivary cortisol
concentration that was recorded after laboratory work
in group I Vs group II, there was a statisticallysignificant increase in the salivary cortisol concentra-
tion in group I compared to group II subjects
(P  0.001) (Table 2 & Fig. 5).
However, the mean value of the salivary CgA con-
centration recorded in group I compared to group II,
there was a statistically significant increase in group I
versus group II subjects (P  0.001) (Table 2 & Fig. 6).
Fig. 5. Comparison of the mean value of the salivary cortisol con-
centration level in group I versus group II.
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Xerostomia is a consequence of many oral and
systemic diseases and is estimated up to 10% of the
general population. Also, xerostomia is a complaint
reported by a large number of post-menopausal
women. So, early assessment of xerostomia may aid
in recognition of treatment in post-menopause stage in
which women are more exposed to systemic diseases.
The measurement of biomarkers in saliva has many
advantages, because it is stress free and allow for
frequent and rapid sampling, whereas diurnal rhythm,
artificial changes due to food or drinking substances,
and blood contamination are some of the disadvantages
[43]. Accordingly, in our study, we used salivary bio-
markers (cortisol and chromogranin A (CgA)) to
investigate relationship between salivary biomarkers
levels and xerostomia in post-menopausal women by
un-stimulated condition.
In a study by Pedersen et al., (2002) [44] and
AghaeHosseini et al., (2010) [45], they reportedFig. 6. Comparison of the mean value of the salivary CgA concen-
tration in group I and group II.significant lowering of stimulated whole salivary flow
rate in post-menopausal women with xerostomia,
compared with post-menopausal women without xero-
stomia. Although this is consistent with our study, the
difference was in use of un-stimulated conditions to
calculate salivary flow rate (SFR). Un-stimulated con-
ditions were more accurate than stimulated conditions
because of difference in type and degree of stimulation.
Our data indicated that un-stimulated whole salivary
cortisol & CgA levels were increased with reduced un-
stimulated whole salivary flow rate in post-menopausal
women suffering from xerostomia (group I) compared
to post-menopausal women not suffering from xer-
stomia (group II), this is in accordance with the findings
of Shigeyama et al., (2008) [42] who also investigated
the salivary levels of cortisol and CgA in subjects with
xerostomia compared to control subjects without xero-
stomia also, their subjects aged were 50ys and over and
added stimulated conditions with un-stimulated condi-
tions. However, our study used aged ranged from 45 to
55ys and did not use stimulated condition.
The findings of the present study were different
from study of Gomez et al., (2006) [37] who found that
there was no significant association between un-
stimulated salivary cortisol levels and post-
menopausal women with xerostomia and no signifi-
cant differences between post-menopausal women with
xerostomia and post-menopausal women without
xerostomia. This might be attributable to smaller
sample size (n ¼ 30) and unclear criteria for the
diagnosis of xerostomia or dry mouth while our study
was done on larger sample size (n ¼ 80) so, criteria of
xerostomia were clear by clinical examinations and
group of questions illustrating presence of xerostomia
which were explained in our method in this study.
On other hand, studies reported on males had
revealed that males had higher secretion rates of un-
stimulated saliva compared with females (post-meno-
pausal women) at age 55ys and over. The differences
were attributed to greater glandular mass in males,
differences in hormonal patterns and differences in
body mass index (BMI). Based on that, studies were
found that xerostomia was more frequent with post-
menopausal women with a range between 24% and
65.1% of them who complained of daily oral dryness
or xerostomia [46e49]. This was going inside with our
study but our study did not deal with male as, com-
parison was between post-menopausal women with
xerostomia and others without xerostomia.
Other studies had indicated that salivary alterations
might be directly related to age rather than disease and/
or drug use in post-menopausal women. This was
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Dodds et al., (2005) [51]who explained that age-related
histological changes in the submandibular glands (used
only once) included atrophy in both secretory acinar
and ductal epithelia, accompanying structural changes
in fibrous and elastic tissues as well as in the walls of
arteries and veins. Accordingly, our exclusion criteria
in this study that patients without systemic diseases or
did not take any medications which might contribute to
xerostomia.
The last opinion by Ship, (1999) [52] and Ship et al.,
(2002) [53] gave results conflicting with ours in that
aging per se lead to a diminution in the capacity of the
salivary glands to produce saliva. They found that many
post-menopausal women complained of a drymouth and
had decreased salivary output, was explained in large as
a reflection of systemic conditions and their treatment
(drugs, chemotherapy and radiotherapy) rather than
being normal squeal of aging. This was not the case in
our study because our exclusion criteria included sys-
temic diseases and treatments which caused xerostomia.
5. Conclusion
From the results of the present study we can conclude
that un-stimulated whole saliva cortisol and chromog-
ranin A levels are higher in post-menopausal women
with xerostomia than in controls which suggests an as-
sociation with symptoms of xerostomia and lower sali-
vary flow rates. Additional studies of salivary biomarkers
(cortisol & CgA) may lead to the development of a
method of monitoring salivary glands functions in sub-
jects suffering xerostomia and early treatment to prevent
complications of xerostomia e.g hypo-salivation which
may results from systemic diseases.References
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